BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 33118175)

  • 1. Is there scope for better individualisation of anthracycline cancer chemotherapy?
    Sallustio BC; Boddy AV
    Br J Clin Pharmacol; 2021 Feb; 87(2):295-305. PubMed ID: 33118175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.
    Vaitiekus D; Muckiene G; Vaitiekiene A; Sereikaite L; Inciuraite R; Insodaite R; Cepuliene D; Kupcinskas J; Ugenskiene R; Jurkevicius R; Juozaityte E
    Cardiovasc Toxicol; 2021 Jan; 21(1):59-66. PubMed ID: 32748118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
    Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
    Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
    Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
    Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
    Bhagat A; Kleinerman ES
    Adv Exp Med Biol; 2020; 1257():181-192. PubMed ID: 32483740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
    Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
    Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
    Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
    van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment-related cardiotoxicity in childhood cancer survivors: Risk factors and follow-up].
    Fresneau B; Fayech C; Butel T; Haddy N; Valteau-Couanet D; Ou P
    Rev Med Interne; 2017 Feb; 38(2):125-132. PubMed ID: 27639916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms rs4673 and rs28714259 in predicting anthracycline-mediated cardiotoxicity in patients with breast cancer.
    Gvaldin GD; Timoshkina TN; Vladimirova L; Svetitskaya SY; Vaschenko VL
    Klin Onkol; 2021; 34(6):463-466. PubMed ID: 34911332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insight into the intraventricular pressure gradient as a sensitive indicator of diastolic cardiac dysfunction in patients with childhood cancer after anthracycline therapy.
    Shigemitsu S; Takahashi K; Yazaki K; Kobayashi M; Yamada M; Akimoto K; Tamaichi H; Fujimura J; Saito M; Nii M; Itatani K; Shimizu T
    Heart Vessels; 2019 Jun; 34(6):992-1001. PubMed ID: 30673819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for
    Chakouri N; Farah C; Matecki S; Amedro P; Vincenti M; Saumet L; Vergely L; Sirvent N; Lacampagne A; Cazorla O
    Theranostics; 2020; 10(18):8130-8142. PubMed ID: 32724462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
    Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
    Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.